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The aim of this study was to develop a 3-D construct carrying an inherent sequential growth factor
delivery system. Poly(lactic acid-co-glycolic acid) (PLGA) nanocapsules loaded with bone morphogenetic
protein BMP-2 and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanocapsules loaded with
BMP-7 made the early release of BMP-2 and longer term release of BMP-7 possible. 3-D fiber mesh
scaffolds were prepared from chitosan and from chitosan–PEO by wet spinning. Chitosan of 4%
concentration in 2% acetic acid (CHI4–HAc2) and chitosan (4%) and PEO (2%) in 5% acetic acid (CHI4–
PEO2–HAc5) yielded scaffolds with smooth and rough fiber surfaces, respectively. These scaffolds were
seeded with rat bone marrow mesenchymal stem cells (MSCs). When there were no nanoparticles the
initial differentiation rate was higher on (CHI4–HAc2) scaffolds but by three weeks both the scaffolds had
similar alkaline phosphatase (ALP) levels. The cell numbers were also comparable by the end of the third
week. Incorporation of nanoparticles into the scaffolds was achieved by two different methods: incor-
poration within the scaffold fibers (NP–IN) and on the fibers (NP–ON). It was shown that incorporation
on the CHI4–HAc2 fibers (NP–ON) prevented the burst release observed with the free nanoparticles, but
this did not influence the total amount released in 25 days. However NP–IN for the same fibers revealed
a much slower rate of release; ca. 70% released at the end of incubation period. The effect of single,
simultaneous and sequential delivery of BMP-2 and BMP-7 from the CHI4–HAc2 scaffolds was studied in
vitro using samples prepared with both incorporation methods. The effect of delivered agents was higher
with the NP–ON samples. Delivery of BMP-2 alone suppressed cell proliferation while providing higher
ALP activity compared to BMP-7. Simultaneous delivery was not particularly effective on cell numbers
and ALP activity. The sequential delivery of BMP-2 and BMP-7, on the other hand, led to the highest ALP
activity per cell (while suppressing proliferation) indicating the synergistic effect of using both growth
factors holds promise for the production of tissue engineered bone.
! 2009 Elsevier Ltd. All rights reserved.
1. Introduction
The limited ability of bone tissue to regenerate in case of large
defects created the need for substitutes which are mostly of auto-
genic and allogenic origin [1]. Tissue engineered constructs
emerged as promising alternatives to these grafts to form viable
and functional 3-D constructs. Polymeric foams [2], micro and/or
nanofiber-based scaffolds [3–5] and rapid prototyped constructs
[6,7] are among the structures that have been successfully
employed as scaffolds for bone tissue engineering; however,
control of cell activity, especially differentiation, within the scaffold
has not been fully achieved in these systems.
Growth factors regulate cellular activities in vivo and their
application as external bioactive agents has been reported to
enhance bone healing [8,9], control growth and differentiation of
cells [10] and stimulate angiogenesis [11]. In nature, multiple
growth factors such as bone morphogenetic proteins (BMPs),
insulin-like growth factor (IGF), fibroblast growth factor (FGF) and
vascular endothelial growth factor (VEGF) function in unison
during bone formation and fracture healing processes [12].
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Among these, BMPs were shown to induce bone formation by
inducing mesenchymal stem cells (MSCs) toward chondroblastic
and osteoblastic differentiation [13]. BMP-2 and BMP-7 were
shown to be the most effective ones that induce complete bone
morphogenesis [14] and were approved by FDA for clinical
applications [15,16]. Considering their mechanism of action, BMP-
2 was reported to be an early appearing factor, peaking at day 1
after fracture, while BMP-7 was expressed approximately after 2
weeks [17]. Therefore, it was considered that delivery of combi-
nations of these growth factors is a viable biomimetic approach
towards bone healing.
The conventional strategy in growth factor therapy for
orthopedic applications is to administer the agent in the form of
a large dose by either single or repeated injections but in such
applications a considerable proportion of the agent was reported
to be lost through leakage and/or loss of bioactivity [12].
Encapsulation of growth factors in carrier structures, therefore,
could be of utmost importance in protecting the bioactivity of
the agent and prolonging its presence at the defect site. There
are various recent attempts in the literature to incorporate
growth factors into scaffold structures in order to provide the
necessary protection and prolongation of activity as well as to
achieve proper control of cellular activities in the implant side
[18–20].
The most recent developments observed in the preparation of
scaffold/controlled delivery systems involve the combined
delivery of several growth factors from the same scaffold. The few
studies in the literature include BMP-2 and transforming growth
factor-b3 (TGF-b3) delivery from alginate hydrogels transplanted
in mice which revealed significant healing [21]. Dual delivery of
VEGF and BMP-2 from gelatin microparticles embedded in porous
degradable scaffolds had a positive effect on repair of a rat cranial
defect [22]. Similarly, sequential delivery of BMP-2 and then IGF-1
from two-layered gelatin coatings led to elevated alkaline phos-
phatase (ALP) activity and mineralized matrix formation in vitro
[23].
Themost recent study in the literature on the combined delivery
of BMP-2 and BMP-7 was reported by our research groupwhere the
growth factors were released from complexed microspheres
embedded in porous poly(lactic acid-co-glycolic acid) (PLGA) scaf-
folds [24]. The positive effect of co-administration of BMP-2 and
BMP-7 on osteogenic differentiation was shown in vitro. In the only
other study also from our group [25], a nano-scale controlled
release system was developed to enable the sequential delivery of
first BMP-2 and then BMP-7 from PLGA and poly(3-hydroxy-
butyrate-co-3-hydroxyvalerate) (PHBV) nanocapsules, respectively.
The effect of various nanoparticle production parameters was
investigated in order to achieve the proper release rates to consti-
tute the parts of the sequential delivery system. Nanocapsules of
PLGA and PHBV were found to have sufficiently high encapsulation
efficiencies, appropriate release rates and smooth surfaces. This
sequential BMP-2/BMP-7 delivery system enhanced the differenti-
ation of MSCs into osteoblasts in vitro while decreasing the prolif-
eration rate.
In the present study, the above mentioned nanoparticulate
sequential delivery system was incorporated into and onto the
fibers of wet spun chitosan-based scaffolds to create bi-functional
constructs serving both as a scaffold and also as the growth factor
delivery system. In the previous study [25], the unentrapped (free)
nanocapsules were used to release both the bovine serum albumin
(BSA) and the BMPs and were found to have similar kinetics, so in
the present study the fiber-incorporated nanocapsules were
expected to behave as before, presenting a similar release kinetics
for the BMPs and the BSA. Therefore, in the current study only the
release kinetics of BSA was studied.
Fibrous scaffolds have gained great attention over the last years
as they have appropriate porosity for cell penetration, nutrient
exchange and tissue ingrowth. These fibrous structures were
produced by electrospinning [4], wet spinning [5] and fiber
bonding [26]. In this study, chitosan fiber mesh scaffolds were used
to house the nanoparticulate sequential growth factor delivery
system. The effect of single, simultaneous and sequential delivery of
BMP-2 and BMP-7 incorporated to the scaffolds by two different
techniques, into and onto chitosan fibers, were studied in vitro
using rat bone marrow MSCs.
2. Materials and methods
2.1. Materials
Low molecular weight chitosan (deacetylation degree 90.85%, i.v. 185 cps for
1% in 1% acetic acid) was purchased from Aldrich. Poly(ethyleneoxide) (PEO)
(Polyox" WSR 301, MW 4 " 106) was obtained from Dow Chemical Company
(USA). PLGA (50:50) (Resomer# RG503H, i.v. 0.32–0.44 dL/g, for 0.1% in chloro-
form, 25 #C) was purchased from Boehringer Ingelheim (Germany). PHBV (PHV
content 8% w/w), dexamethasone, b-glycerophosphate disodium salt, L-ascorbic
acid were bought from Sigma–Aldrich (Germany). BSA and polyvinyl alcohol
(PVA) (MW 15,000) were from Fluka (USA). BMP-2 from InductOs kit (Medtronic,
USA) and recombinant human BMP-7 from Ray Biotech (USA) were used as the
growth factors. Quantikine BMP-2 immunoassay from R&D Systems (USA) and
human BMP-7 Elisa kit from Ray Biotech (USA) were used in the determination
of the growth factors. Dulbecco’s Modified Eagle Medium (DMEM, high glucose),
fetal bovine serum (FBS) were obtained from Hyclone (USA). NucleoCounter
reagents were supplied by Chemometec (Denmark) and Alamar Blue cell
proliferation assay was from USBiological. For the assessment of cell differen-
tiation, alkaline phosphatase kit (Randox, USA) was used.
2.2. Preparation of BSA, BMP-2 and BMP-7 loaded nanocapsules
PLGA and PHBV nanocapsules containing BMP-2 and BMP-7, respectively, or BSA
in both type of nanocapsules, were prepared by the double emulsion-solvent
evaporation technique as reported earlier [25]. Briefly, an aqueous solution of BSA or
BMPwas emulsified in dichloromethane containing PLGA or PHBV and this was then
introduced to an aqueous solution containing PVA. Nanocapsules were collected by
centrifugation and washed with Tris–HCl (pH 7.4). The nanocapsules were then
resuspended in the buffer and lyophilized.
2.3. Chitosan-based fiber mesh scaffold production
Chitosan-based 3-D fiber mesh scaffolds were prepared by wet spinning of
chitosan and chitosan/PEO blends according to the procedure described before [3].
Briefly, chitosan and chitosan/PEO were dissolved in aqueous acetic acid. These
solutions were then injected into a coagulation bath of Na2SO4 (0.5 M), NaOH (1 M)
and distilled water (3:1:6 v/v) in which they were kept overnight. After exhaustive
washing with distilled water, fibers were dehydrated with methanol and then dried
in a mould. Chitosanwas blended with PEO to study its effect on the mechanical and
structural properties of the construct. The effect of chitosan concentration, PEO
addition and acetic acid concentration were studied by preparation of the samples
listed in Table 1.
2.4. Micro-computed tomography
Mean porosity and porosity distribution of the 3-D scaffolds were assessed by
using micro-computed tomography (m-CT 20, SCANCO Medicals, Switzerland).
Scanner settings were 40 keV and 248 mA. Entire scaffolds were scanned in slices of
7 mm thickness. CT Analyser and CT Vol Realistic 3-D Visualization (SkyScan,
Belgium) softwares were used for image processing in CT reconstructions, and in
creation and visualization of the 3-D representations.
Table 1
Components of chitosan-based scaffolds and their compositions.
Sample code Surface
topography
Concentration in final solution
Chitosan
(%) (w/v)
PEO
(%) (w/v)
Acetic
acid (%) (v/v)
CHI4–HAc2 Smooth 4 – 2
CHI6–HAc2 Rough 6 – 2
CHI4–PEO2–HAc2 Smooth 4 2 2
CHI4–PEO2–HAc5 Rough 4 2 5
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2.5. Incorporation of the nanoparticles into chitosan scaffolds
Incorporation of PLGA and PHBV nanocapsules into chitosan-based fiber mesh
scaffolds was carried out by two methods: incorporation within the fibers (NP–IN)
or on the fibers (NP–ON). For incorporationwithin the fibers (NP–IN), particles were
mixed with chitosan or chitosan/PEO solutions before the wet spinning process.
NP–ON particle loading was done by introducing 100 mL of nanocapsule suspension
onto the both sides of the scaffolds and applying a series of vacuum–pressure cycles.
The scaffolds were then dried overnight under vacuum and stored in a desiccator.
For the BMP loaded particle incorporated scaffolds, 40 ng BMP/scaffold was used for
all conditions. For both NP–IN and NP–ON cases, single delivery of BMP-2 and BMP-7
was achieved by their encapsulation within PLGA and PHBV nanocapsules, respec-
tively, and by their single incorporation to the constructs. For the simultaneous case,
both BMP-2 and BMP-7 were encapsulated in PLGA nanocapsules, therefore,
performing the rapid release of both BMPs from the constructs. The sequential
delivery, on the other hand, was achieved by encapsulation of BMP-2 in PLGA and
BMP-7 in PHBV nanocapsules and thus achieving two different release rates.
2.6. In situ release studies
Release from the nanoparticle incorporated constructs was simulated by using
BSA as a model molecule to represent growth factors. Protein release was deter-
mined spectrophotometrically by using Coomassie Plus Assay (Pierce, USA).
2.7. Cell culture
Bone marrow MSCs were isolated from 6 weeks old, male Sprague–Dawley
rats as reported earlier [27]. The rats were euthanized and their femurs and tibia
were excised, washed with DMEM containing 1000 U/mL penicillin and 1000 mg/
mL streptomycin under aseptic conditions. The marrow in the midshaft was
flushed out with DMEM containing 20% FBS and 100 U/mL penicillin and 100 mg/
mL streptomycin, the cells were centrifuged at 500g for 5 min, and the resulting
cell pellet was resuspended and plated in T-75 flasks. These primary cultures were
incubated for 2 days. The hematopoietic and other unattached cells were removed
from the flasks by repeated washes with phosphate buffered saline (PBS) (10 mM,
pH 7.4) and the medium of the flasks was renewed every other day until
confluency was reached. These primary cultures were then stored frozen in liquid
nitrogen until use. Ethylene oxide (EtO) sterilized fiber mesh scaffolds and
nanoparticle incorporated constructs were then seeded with these cells at
a seeding density of 50,000 cells/scaffold. The viable cell number during cell
seeding was determined with the Nucleocounter (Chemometec, Denmark).
Incubation was performed at 37 #C and 5% CO2 in DMEM supplemented with 10%
FBS, 10 mM b-glycerophosphate, 50 mg/mL L-ascorbic acid, 10 nM dexamethasone
and penicillin/streptomycin/amphotericin B. Viable cell number was assessed
with Alamar Blue assay (USBiological). ALP activity was determined by using
Randox kit (USA) where the absorbance of p-nitrophenol formed from p-nitro-
phenyl phosphate was measured at 405 nm.
2.8. Scanning electron microscopy
The structure of the scaffolds, nanocapsule incorporated constructs and the cell
attachment on the fiber surfaces after 21 days of incubation were studied by
Scanning Electron Microscopy (SEM) after sputter coating with gold (Leica Cam-
bridge S360, Germany). Cell seeded scaffolds were fixed after 21 days of incubation
with glutaraldehyde (2.5% in cacodylate buffer, pH 7.4) for 2 h and thenwashed with
cacodylate buffer several times and lyophilized prior to SEM examination.
2.9. Statistical analysis
The data from the MSC proliferation and differentiation assays (n ¼ 3) were
analyzed with statistically significant values defined as p < 0.05 based on one-way
analysis of variance (ANOVA) followed by Tukey’s test for determination of the
significance of difference between different groups (p % 0.05).
3. Results and discussion
3.1. Wet-spun chitosan-based fiber mesh production
Chitosan-based 3-D fiber mesh scaffolds were produced by wet
spinning. The effect of polymer (chitosan) concentration, compo-
sition (chitosan, PEO) and the solvent (acetic acid) concentration on
the properties of fibers were studied.
Initially, the effect of concentration of pure chitosan on the
structure of the fibers produced was investigated by using 4% (CHI4–
HAc2) and 6% (CHI6–HAc2) chitosan solutions. Chitosan solutions
less concentrated than 4% did not allow the formation of fibrous
structures. It was observed that 4% chitosan solution was the best in
terms of ease of fiber production and fiber surface smoothness
whereas use of 6% chitosan gave rough surfaced fibers (Fig. 1). 8%
chitosan did not even allow the formation of proper fibrous structure.
After the selection of 4% chitosan solution as the optimal concen-
tration to prepare smooth fibers, it was further modified by blending
with PEO in order to improve the structural properties. Chitosan (4%)
was blended with PEO at 2:1 ratio, creating chitosan (4%)/PEO (2%)
fibers (CHI4–PEO2–HAc2) (Fig. 2). It was observed that introduction of
PEO resulted in improved stability of the scaffold.However, additionof
PEO more concentrated than 2% created solutions that were too
viscous to be spun into proper fibers. The effect of PEO presence could
be observed by comparing Figs. 1b and 2b inwhich chitosan (4%) and
Fig. 1. CHI4–HAc2 fiber mesh scaffold, (a) "15, (b) "100, (c) "1000; CHI6–HAc2 fiber mesh scaffold, (d) "15, (e) "100, (f) "1000. Bar represents (a,d) 2 mm, (b,e) 200 mm, (c,f) 20 mm.
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chitosan (4%)/PEO (2%) fibers produced in 2% acetic acid are presented.
PEO did not alter the smoothness of the fiber surfaces; however,
resulted in increased fiber thickness, as expected due to increased
total polymer concentration (ca. 100 mm vs. ca. 125 mm).
Meanwhile, the effect of concentration of solvent on surface
topography of the chitosan (4%)/PEO (2%) fibers was studied by
using 2% and 5% (v/v) acetic acid. It was observed that the more
dilute acetic acid solution leads to smoother surfaces (Fig. 2).
Among the samples investigated, two scaffolds onewith smooth
(CHI4–HAc2) and one with rough (CHI4–PEO2–HAc5) fiber surface
were selected for further investigation as the surface properties are
known to make a difference in cell–material interactions through
altered surface chemistry and roughness (Table 1). Scaffolds of
CHI4–HAc2 with a smooth fiber surface, and CHI4–PEO2–HAc5
with a rough surface were used in the incorporation of the
sequential delivery system.
3.2. Characterization of the scaffolds
The porosity and porosity distribution throughout the thickness
of the scaffolds were investigated by m-CT. Analysis revealed that the
porosity of the scaffolds was not influenced significantly by the
chitosan and chitosan/PEO concentration and composition. The
porosity values for CHI4–HAc2 and CHI4–PEO2–HAc5 scaffolds were
85.4% and 86.7%, respectively. The porosity distribution throughout
the thickness of CHI4–HAc2 scaffold is presented in Fig. 3. It was
observed that the poreswere completely interconnected throughout
the whole structure. Moreover, the porosity profile showed that the
porosity from top to bottom of the scaffold did not have a significant
change. The outermost part of the scaffold has higher porosity (ca.
98%) which reduces to ca. 85% through the bottom. This is especially
important when most scaffolds produced by other methods do not
have complete connectivity and the porosity decreases significantly
from the surface towards the core leading to insufficient population
and oxygen/nutrient concentrations in the core.
The change in properties for CHI4–HAc2 and CHI4–PEO2–HAc5
scaffolds in wet state during 21 days was investigated in sterile PBS
(pH 7.4) at 37 #C and 5% CO2 conditions. After 21 days of incubation
in the medium, the dimensions and the weight of the fibers were
altered significantly (Table 2). Both scaffolds swelled as soon as they
were put into the medium and became 500–600% (w/w) heavier.
The increase in individual fiber thickness was also significant;
around 55% for both scaffolds. The diameter and height of both
scaffolds were also increased, by about 20% for both of them.
The porosity of the scaffolds was measured before hydration
using a m-CT. In the hydrated state the porosity was calculated (from
the scaffold volume and the fiber thicknesses) to be decreased by
about 15% for CHI4–HAc2 and 25% for CHI4–PEO2–HAc5. These
changes are much smaller than the increase in the fiber thicknesses
upon hydration (ca. 55%) possibly because of the restraint imposed
by the meshwork of the scaffold.
Fig. 2. CHI4–PEO2–HAc2 fiber mesh scaffold, (a) "15, (b) "100, (c) "1000; CHI4–PEO2–HAc5 fiber mesh scaffold, (d) "15, (e) "100, (f) "1000. Bar represents (a,d) 2 mm,
(b,e) 200 mm, (c, f) 20 mm.
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Fig. 3. Porosity distribution throughout the thickness of CHI4–HAc2 scaffold.
Table 2
Changes in chitosan-based scaffold properties after incubation in sterile PBS (pH 7.4)
for 21 days.
CHI4–HAc2 CHI4–PEO2–HAc5
Fiber thickness (%) 53 59
Scaffold diameter (%) 18 29
Scaffold height (%) 25 29
Scaffold weight (%) 600 500
P. Yilgor et al. / Biomaterials 30 (2009) 3551–35593554
SEM was done to examine the changes in surface properties for
both scaffolds after 21 days of incubation in situ. Micrographs of
CHI4–HAc2 scaffolds revealed that there was almost no change in
the fiber appearance at the end of 21 days of incubation; however,
PEO had dissolved out of CHI4–PEO2–HAc5 scaffolds leading to
increased surface roughness (Fig. 4).
3.3. MSC culture on chitosan-based fiber mesh scaffolds
Suitability of chitosan-based fiber mesh scaffolds for potential
use in bone tissue engineering applications were studied using rat
bone marrow MSCs. It was observed that although cell numbers
were almost the same after 21 days, initial cell proliferation rate
during the first week was higher on CHI4–HAc2 scaffolds then on
CHI4–PEO2–HAc5 (Fig. 5) which was followed by a lag period for
CHI4–HAc2 scaffolds. In this lag period of cell proliferation between
7 and 14 days, the increase in ALP activity, the indicator for MSC
differentiation, was higher for CHI4–HAc2 when compared to
CHI4–PEO2–HAc5 scaffolds and the difference was statistically
significant at all time points (p < 0.01) (Fig. 6). The change in cell
proliferation was statistically significant after the first week of
incubation for CHI4–HAc2 scaffolds (p < 0.05). Cell proliferation
and ALP activity were shown to increase gradually during 21 days of
incubation for blend scaffolds. ALP activities were reported as
specific activity, the ALP activity per cell.
SEM analysis revealed that cells attached and spread well on
both scaffolds after 21 days of incubation (Fig. 7). It is seen that the
smooth chitosan fibers became rougher in case of cell presence
after 21 days and the shapes of the cells indicate a proper spread.
On CHI4–PEO2–HAc5 fibers the roughness is maintained and the
cell spread is very well.
3.4. Incorporation of sequential delivery system into
chitosan-based scaffolds
In order to incorporate the nanoparticles into chitosan-based
scaffolds, two different approaches were used: nanoparticles were
introduced within the chitosan-based fibers (NP–IN) or nano-
particles were incorporated onto the fibers (NP–ON).
The nanoparticles were introduced into the chitosan-based
fibers by mixing the nanoparticles with chitosan and chitosan/PEO
solutions followed by spinning to produce fibers containing the
nanoparticles within their structure. PLGA nanocapsules incorpo-
rated into CHI4–HAc2 scaffolds are clearly visible due to increased
roughness as unloaded fiber surfaces were smooth. The observation
is difficult in CHI4–PEO2–HAc5 fibers, however, as unloaded fibers
were also rough (Fig. 8).
In the second method, particles were seeded onto the CHI4–
HAc2 scaffolds after the preparation of both the fibers and the
nanocapsules leading to the attachment of the particles onto the
fiber surfaces (Fig. 9). Here the particles appear to have adhered
properly onto the fibers. In this incorporation method (NP–ON),
Fig. 4. Fiber structure after 21 days of incubation for (a) CHI4–HAc2, (b) CHI4–PEO2–HAc5 scaffolds.
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only CHI4–HAc2 scaffolds were used with smooth fiber surfaces to
properly demonstrate incorporation of the particles onto the fiber
surfaces.
The release of BSA, a model protein, from the particle incorpo-
rated (NP–ON) and (NP–IN) constructs (CHI4–HAc2) was studied
and compared with that of free nanoparticles. It was observed that
although not influencing the overall release pattern, incorporation
into the scaffolds (onto the fibers, NP–ON) suppressed the burst
release in addition to slowing down the release for the rest of the
period for both PLGA and PHBV nanocapsules (Fig. 10). The main
difference in the release rates for both nanoparticles was observed
during the first 3 days of the incubation where suppression in
BSA release rates was observed. As described previously, PLGA
nanocapsules, either free or incorporated in the scaffold structure,
released their contents faster than PHBV counterparts which is why
they were selected to serve as the early stage release component of
the sequential delivery system. While the protein encapsulated in
PLGA nanocapsules was almost completely released, both the free
and the incorporated PHBV nanocapsules did not release their total
content in the 21 days of the test. On the other hand, PLGA particles
Fig. 7. MSC attachment and spreading on (a,b) CHI4–HAc2; (c,d) CHI4–PEO2–HAc5 scaffolds after 21 days of incubation.
Fig. 8. PLGA nanocapsules incorporated in (NP–IN) (a) CHI4–HAc2 scaffold, (b) CHI4–PEO2–HAc5 scaffold ("1000 in all micrographs). Inset pictures are unloaded counterparts.
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incorporated in the fibers of CHI4–HAc2 scaffolds (NP–IN) revealed
a much slower release rate, even slower than with NP–ON. It was
observed that at the end of the incubation period of 25 days only
70% of the content was released from the NP–IN construct. The
release of the content apparently is affected by the location of the
drug carrying nanoparticles. When they are on the fiber there is
only the diffusional restriction due the tortuosity of the path of the
drug due to the fibers of the scaffold. When in the fiber, there is an
additional diffusion restriction due to the drug traversing the fiber
thickness.
The advantage of using nano-size particles and the incorpora-
tion approach (NP–IN and NP–ON) used in the delivery of BMP over
use of free molecules is that the release from the capsules is
controlled by the capsule wall properties. Especially in the NP–ON
case, the release could be fine-tuned easily by changing the nano-
particle properties. When the incorporation within the fibers
(NP–IN) is considered, it is deduced that the use of chitosan as the
scaffold material is advantageous because it can swell (up to 600%,
Table 2) and the release from the nanocapsules probably takes
place first into the fiber and then out the fiber into the release
medium further prolonging the release of the molecules from the
fibrous scaffold.
Fig. 9. Incorporation of PLGA nanocapsules onto CHI4–HAc2 scaffold (NP–ON), (a) "200, (b) "2000.
Fig. 10. Release of BSA from free and incorporated particles.
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3.5. Influence of sequential BMP-2/BMP-7 delivery from
constructs on MSC proliferation and differentiation
The effect of single, simultaneous, and sequential delivery of
BMP-2 and BMP-7 released from constructs was investigated in
vitro using rat bone marrowMSCs with two different incorporation
methods. However, only one type of scaffold (CHI4–HAc2), with
a smooth fiber surface and a higher initial MSC differentiation rate
(Fig. 6), was used for the incorporation of BMP loaded nanoparticle
incorporation studies. The simultaneous delivery of two growth
factors was achieved by encapsulating both growth factors in PLGA
nanocapsules. Therefore, in this condition both BMP-2 and BMP-7
were released to the medium in the beginning of the incubation.
The difference observed in cell proliferation and differentiation
through different administration routes of BMPs suggested that
the growth factors were released in a bioactive form from the
constructs for an extended period.
For every condition tested, particles incorporated on the fiber
surfaces (NP–ON) led to higher cell numbers compared to particle
incorporation within the fibers (NP–IN) indicating higher concen-
tration due to higher rate of release of the growth factors (Fig. 11).
The change in cell proliferation was significant at all times for all
conditions (p % 0.05, details given on the figure). Moreover, BMP-7
increased cell proliferation more than BMP-2 but had the lowest
differentiation. Simultaneous delivery led to second highest prolif-
eration rate. Sequential delivery had the lowest cell proliferation, but
the highest ALP activity (Fig. 12) indicating higher cellular differen-
tiation in case of sequential delivery of BMP-2 and BMP-7. The
differences between ALP activity results were statistically significant
at all time points for all conditions, as well (p< 0.001). Simultaneous
delivery of two growth factors, on the other hand, failed to give high
ALP activity results basically because proliferation was the stimu-
lated biological mechanism rather than differentiation.
Cell number on chitosan fiber mesh scaffolds without loading
with any BMPs (CHI4–HAc2) on day 7, 14 and 21 were 3.7*105 &
9*104, 4.2*105 & 7*104 and 5.4*105 & 1*105 respectively (Fig. 5),
were higher compared to the scaffolds loaded with the BMPs and
this indicates the suppression of cell proliferation in the presence of
BMPs regardless of the delivery condition.
4. Conclusion
In the present study, two bone growth factors, BMP-2 and
BMP-7, were encapsulated in PLGA and PHBV nanocapsules which
were then incorporated into fibrous chitosan scaffolds. The system
constructed by the incorporation of two populations of nano-
capsules to deliver the BMPs in a sequential manner performed
better in inducing differentiation (ALP activity) than individual
nanocapsule populations or the populations designed to provide
simultaneous release of the BMPs. Of the sequential delivery
systems, the one with the nanocapsules attached on the fibers
performed better than the one where the nanocapsules were
embedded in the fiber structure. It can be stated that sequential
growth factor delivery is a better approach than individual growth
factor use for tissue engineering due to its mimicking the natural
process of healing.
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